Literature DB >> 9100764

Fine needle aspiration of breast masses. An analysis of 1,398 patients in a community hospital.

F Domínguez1, J R Riera, S Tojo, P Junco.   

Abstract

OBJECTIVE: To determine the diagnostic efficacy of breast fine needle aspiration (FNA) in the routine practice of a community hospital. STUDY
DESIGN: The study group consisted of 1,398 consecutive FNA biopsies of the female breast performed at our institution during a five-year period; 450 (32%) had histologic follow-up. Both FNA and the histologic diagnosis were compared in order to establish the accuracy, efficiency and safety of the FNA breast technique.
RESULTS: The sensitivity of the FNA procedure was 93.49% and specificity 95.73%, with a predictive value for a positive diagnosis of 93.49% and for a negative diagnosis, 95.73%. The overall diagnostic accuracy was 94.84%, and the sensitivity of cytologic diagnosis was 98.75%. The false negative and false positive rates were 2.5%, including 10 cases with suspicious diagnoses and only 1 false positive diagnosis (0.23%). The false positive and false negative cases were recorded as having no effect or a minimal effect on patient management, and no mastectomy was performed because of this FNA diagnosis.
CONCLUSION: FNA breast biopsy is an efficient tool for diagnosis when performed by surgical pathologists with cytologic training but not exclusively dedicated to cytopathology.

Entities:  

Mesh:

Year:  1997        PMID: 9100764     DOI: 10.1159/000332522

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  2 in total

1.  Cytological study of palpable breast lumps presenting in an Indian rural setup.

Authors:  Smita Balwantrao Sankaye; Suyrakant Dattatreya Dongre
Journal:  Indian J Med Paediatr Oncol       Date:  2014-04

Review 2.  Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature.

Authors:  Suvradeep Mitra; Pranab Dey
Journal:  Cytojournal       Date:  2016-08-31       Impact factor: 2.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.